Pfizer says cancer therapy beats standard therapy in late-stage blood cancer study

Pfizer Inc. PFE on Wednesday shared topline results from the late-stage study of its cancer treatment, ELREXFIO (elranatamab) ...

Pfizer Says Blood-Cancer Treatment Meets Goal in Late-Stage Study

Pfizer said its blood-cancer treatment met the main goal of an ongoing late-stage study, significantly extending the time patients lived without their disease worsening compared with a standard drug ...

Pfizer posts late-stage trial win for multiple myeloma therapy Elrexfio

Pfizer (PFE) stock is in focus as a trial for the company's Elrexfio multiple myeloma drug hit the main goal with patients on ...
Fierce Pharma

Pfizer looks to jump start Elrexfio with topline win in second-line myeloma

Nearly three years after the FDA approved Pfizer's bispecific antibody Elrexfio as a late-line treatment for patients with ...
The Caledonian-Record

Pfizer’s ELREXFIO Significantly Improves Progression-Free Survival for Double-Class Exposed Patients with Relapsed or Refractory Multiple Myeloma

(NYSE: PFE) today announced positive topline results from the Phase 3 MagnetisMM-5 study evaluating ELREXFIO ® (elranatamab) as monotherapy in adults with relapsed or refractory multiple myeloma (RRMM ...
BioSpace

Pfizer culls early PD-L1 asset after series of clinical wins, deals in cancer

Pfizer’s decision to cut its early-stage cancer asset was due to “strategic business reasons” and not driven by safety or ...